Mersana Therapeutics, Inc. (MRSN)
MRSN Stock Price Chart
Explore Mersana Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze MRSN price movements and trends.
MRSN Company Profile
Discover essential business fundamentals and corporate details for Mersana Therapeutics, Inc. (MRSN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 Jun 2017
Employees
102.00
Website
https://www.mersana.comCEO
Martin H. Huber
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
MRSN Financial Timeline
Browse a chronological timeline of Mersana Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$1.44, while revenue estimate is $14.20M.
Earnings released on 13 Aug 2025
EPS came in at -$4.08 falling short of the estimated -$3.75 by -8.80%, while revenue for the quarter reached $3.06M , missing expectations by -71.24%.
Stock split effective on 28 Jul 2025
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 15 May 2025
EPS came in at -$4.75 surpassing the estimated -$5.25 by +9.52%, while revenue for the quarter reached $2.75M , missing expectations by -55.01%.
Earnings released on 3 Mar 2025
EPS came in at -$0.11 surpassing the estimated -$0.16 by +31.25%, while revenue for the quarter reached $16.36M , beating expectations by +162.30%.
Earnings released on 13 Nov 2024
EPS came in at -$0.09 surpassing the estimated -$0.18 by +50.00%, while revenue for the quarter reached $12.60M , beating expectations by +64.88%.
Earnings released on 13 Aug 2024
EPS came in at -$0.20 falling short of the estimated -$0.18 by -11.11%, while revenue for the quarter reached $2.29M , missing expectations by -73.70%.
Earnings released on 9 May 2024
EPS came in at -$0.16 surpassing the estimated -$0.18 by +11.11%, while revenue for the quarter reached $9.25M , beating expectations by +8.73%.
Earnings released on 28 Feb 2024
EPS came in at -$0.16 surpassing the estimated -$0.20 by +20.00%, while revenue for the quarter reached $10.70M , beating expectations by +17.08%.
Earnings released on 7 Nov 2023
EPS came in at -$0.35 falling short of the estimated -$0.31 by -12.90%, while revenue for the quarter reached $7.70M , missing expectations by -11.11%.
Earnings released on 8 Aug 2023
EPS came in at -$0.47 falling short of the estimated -$0.39 by -20.51%, while revenue for the quarter reached $10.65M , missing expectations by -17.73%.
Earnings released on 9 May 2023
EPS came in at -$0.52 falling short of the estimated -$0.41 by -26.83%, while revenue for the quarter reached $7.80M , missing expectations by -57.34%.
Earnings released on 28 Feb 2023
EPS came in at -$0.44 surpassing the estimated -$0.47 by +6.38%, while revenue for the quarter reached $14.69M , missing expectations by -3.90%.
Earnings released on 7 Nov 2022
EPS came in at -$0.61 falling short of the estimated -$0.09 by -577.78%, while revenue for the quarter reached $5.57M , missing expectations by -90.19%.
Earnings released on 8 Aug 2022
EPS came in at -$0.55 falling short of the estimated -$0.50 by -10.00%, while revenue for the quarter reached $4.28M , beating expectations by +94.55%.
Earnings released on 9 May 2022
EPS came in at -$0.59 falling short of the estimated -$0.31 by -90.32%, while revenue for the quarter reached $2.04M , missing expectations by -88.19%.
Earnings released on 28 Feb 2022
EPS came in at -$0.68 falling short of the estimated -$0.67 by -1.49%, while revenue for the quarter reached $11.00K , beating expectations by +106.26%.
Earnings released on 9 Nov 2021
EPS came in at -$0.63 falling short of the estimated -$0.58 by -8.62%, while revenue for the quarter reached $11.00K , missing expectations by -89.00%.
Earnings released on 6 Aug 2021
EPS came in at -$0.59 falling short of the estimated -$0.50 by -18.00%, while revenue for the quarter reached $11.00K , missing expectations by -92.14%.
Earnings released on 10 May 2021
EPS came in at -$0.50 falling short of the estimated -$0.39 by -28.21%, while revenue for the quarter reached $11.00K , beating expectations by +39.29%.
Earnings released on 26 Feb 2021
EPS came in at -$0.42 falling short of the estimated -$0.33 by -27.27%, while revenue for the quarter reached $11.00K , beating expectations by +45.46%.
Earnings released on 9 Nov 2020
EPS came in at -$0.33 falling short of the estimated -$0.31 by -6.45%, while revenue for the quarter reached $11.00K , beating expectations by +11.12%.
MRSN Stock Performance
Access detailed MRSN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.